5th Global Summit & Expo on
Pharmaceutics, Drug Discovery and Nanoscience

Bruno Sarmento is Principal Investigator at INEB/i3S, Institute of Biomedical Engineering/Institute for Investigation and Innovation in Health, University of Porto, and Assistant Professor at IUCS, Instituto Universitário de Ciências da Saúde, Portugal. He graduated in Pharmaceutical Sciences at the University of Porto (UP) in 2002 and completed a PhD in Pharmaceutical Nanotechnology at UP in 2007, in collaboration with Queen's University (CA), University of Copenhagen (DK) and University of Santiago de Compostela (ES). He also co-founded Inovapotek in 2008, and is member of its advisory board. In 2012 he became Associated Researcher at INEB, where established an independent team. He was Visiting Professor of the Post-Graduate School, UniOeste (BR) and is now Visiting Research Professor at Queen's University, Belfast (UK). So far, he has supervised/co-supervised 10 Post-Docs, 34 PhD students (19 completed) and 27 MSc students (24 completed), and 10 researcher assistants. He attracted direct competitive funding worth more than 8 M€, at national and international levels. His current research is focused on the development of functionalized nanomedicines and their application in the pharmaceutical and biomedical fields. In particular, nanoformulations of biopharmaceutical drugs with interest in diabetes, cancer and infectious diseases. He has also specialized in mucosal tissue engineering models to validate functionalized nanomedicines and to perform in vitro/in vivo correlation. He published more than 300 papers in international peer reviewed journals, total citations in Scopus 7634; H-index 43 and in GoogleScholar 10000; H-index 47), 48 book chapters and more than 200 proceedings. He edited 5 books, participated in more than 50 invited/selected talks in national and international meetings and was awarded several distinctions. He is editor of European Journal of Pharmaceutical Sciences, and member of the Editorial Advisory Board of 10 international journals.

Pharmaceutical Nanotechnology

Prof. Dr. Heyam Saad Ali, Ph-D –She is working in the pharmaceutics department in Dubai Pharmacy College, UAE. Prof. contributed more than 70 articles to reputed international scientific journals and conferences, in different conventional, controlled and targeted drug delivery systems in pharmaceutical product development. She has been invited as a speaker at numerous International conferences.Reviewer and member of editorial board of many international journals.

pharmaceutics

He is research concentrated mainly on metal toxicology, with emphasis on the mechanisms by which metals cause nephrotoxicity and hepatotoxicity. His laboratory also investigated the biomarkers of renal dysfunction in both occupationally- and environmentally-exposed populations in the United States and Japan. His research in more recent years shifted to investigating the role of cadmium in breast cancer progression. Dr. Shaikh chaired the Department of Pharmacology and Toxicology and later the Department of Biomedical Sciences in the College of Pharmacy from 1985 to 2003. He was also the Director of NIH grant-supported state-wide RI-INBRE Program from 2001 to 2018. In this capacity, he fostered the recruitment and research career development of junior faculty, postdoctoral fellows, and students, and promoted collaborative biomedical and behavioral research among the junior and senior faculty from the University of Rhode Island, Brown University and five primarily undergraduate institutions.

Toxicity of metals and nephrotoxicity

Kate ONeill, DNP, RN has over 25 years’ experience in the healthcare industry and is Sr. Advisor Practice, Education and Innovation at iCareQuality.us. Over the past 6 years she has served as a Subject Matter Clinical Expert collaborating with engineers and informatics teams with practice innovation, project development, and system implementation at the learning labs in Philadelphia and Toronto. As an healthcare leader, Dr. ONeill works with key industry stakeholders to develop evidence-based solutions to improve provider engagement with focus on reducing ALL CAUSE HARM. Dr. ONeill also has deep expertise in frontline clinical practice with over 20 years in emergency medicine where she was awarded textbook of the year for Pediatric Triage Guidelines; served as ER Staff Development Educator; and developed the first clinical ladder program to measure skills, competencies and nursing performance. She served as the Senior Nursing Editor for PEMSoft and the journal Pediatric Emergency Care. Kate received a US patent for designing a medical device bite block for cervical spine radiography; and in 2009, she received the Bayaida Business Award at Drexel University for new technology development. Additionally, while at Drexel, she collaborated with nursing faculty and led the simulation team to develop an online platform for evidence-based practice to measure competencies in the student practice setting. Kate has other advanced skills and capabilities including hospital compliance, patient safety, risk management, quality improvement, LEAN and health information technology (HIT).

Healthcare,Clinical Research

Dr. Carolle-Laure KPOUMIE has worked as pediatric assistant physician in pediatric’s department of faculty of medicine in Cameroon, as clinical researcher methodology, scientific writing, public health, oncology, internal medicine and continued her career in pharmaceutical industries in France. She participates in many congress with studies made in hospitals on relevant cases in the framework Studies and clinical research. She became head of department, director, head of district where she continued her research, writing of treatment protocols in different departments for common pathologies encountered in her context, managing Epidemic crisis such as cholera, meningitis, avian influenza, yellow fever and organizes campaigns on infectious diseases ,HIV, cardiovascular diseases, family planning, research on severe malaria, malnutrition in Children and participates in studies on neonatal mortality in underdeveloped countries. She work on ADR in hospital following drug administration, pharmacovigilance, vaccinovigilance, biovigilance, materiovigilance, pharmacovigilance in underdeveloped countries, articles, medical information and therapeutic safety, clinical trials, Post-marketing, and other’s studies.

Drug Safety

PhD (Specialist in Genetic Toxicology; Univ. Autónoma de Barcelona) and Bachelor of Pharmacy (Univ. Central de las Villas, Cuba). Current position: Senior Toxicologist & Nonclinical Safety Adviser, at Ferrer Advanced Biotherapeutics. Ferrer Internacional. Previous positions: Pharmacovigilance Officer/Senior Nonclinical Toxicologist (Ferrer); Medical Adviser. Dermatology Area (Ferrer); Senior Toxicologist. Head of In vivo Toxicology Group (Ferrer); Senior Nonclinical Toxicology Study Director (RCC-CIDA s.a.l.). Senior Toxicologist/Nonclinical Safety with more than 15 years of experience working in the design and management of several fields of nonclinical toxicology and safety issues to support the efficacy/safety in the R&D in New Development Projects with the aim to obtain new medicinal products. Co-author of over 12 peer-review of scientific publications. Invited Speaker at 20 Scientific Events in the last 10 years at international congress. Expert of European Commission: Sixth and Seven Framework Programme. Area Preclinical Toxicology and Mutagenesis. Expert Member Panel in Innovative Medicines Initiative (IMI)-Scientific Panel to evaluate the proposals for the IMI2 9th Call: topic on ‘Next generation of electronic translational safety–NexGETS. Member of Editorial Board of scientific journals and several Organizing Committee of Scientific Congress. Member of Jury several doctoral theses (Univ. Autónoma de Barcelona. Current interests: Open innovation & Collaborative Bio-Research. Advanced Therapies. Neuropharmacology. Ophthalmology. Molecular diagnostics and other Therapeutic areas.

Pharmacovigilance

Gopal Natesan has completed his Doctoral degree (PhD) in Pharmaceutical Chemistry from Hamdard University (Jamia Hamdard) New Delhi, India in 2000 and currently serving as Professor of Medicinal Chemistry & Deputy Dean of Research & Innovation and Students Affairs in Faculty of Pharmacy, MAHSA University, Kuala Lumpur, Malaysia. His research focuses on the synthesis of newer small chemical entities, quinazolinones heterocyclic pharmacophore and their preliminary screening in both in-vivo and in-vitro models mainly focusing on pain & inflammation and also for newer microbial agents. He has published >40 articles in indexed journals and presented >80 papers in conferences and invited speaker at international scientific meetings and conferences and serves as reviewer for several scientific international journals and also as Editorial/Advisory board of various journals.

Pharmaceutical Chemistry

Paul Stannard has worked internationally in the US, Europe, Middle East and Asia and spoke at Davos 2019 about the next industrial revolution (Industry 4.0) and the impact on Smart Cities and how Nanoscale technologies will change the world in almost every area of life including sustainable healthcare, energy, food production, transport, infrastructure, AI and telecoms and communications.Chairman of The World Nano Foundation for the commercialisation of nanotechnology. Chairman of Trustees for World Science Aid and Chairman and Founder of Nano Media Group who are launching an investment funding programme where Nanotechnology research and IP can be potentially used as a tangible asset for funding and investment. He is also Chairman of Enabling Tech Capital based in London. He is a passionate advocate for Nanomedicine, Nano materials as well as other Nano enabled technologies which create significant global value and impact as well as sustainability for everyone.

Nanotechnology

Experienced Associate Professor Of Radiopharmaceutical Chemistry with a demonstrated history of working radioisotopes and radiopharmaceuticals. Skilled in Pharmaceutical Research, Life Sciences, Radiopharmaceuticals, Science, and Nuclear Magnetic Resonance (NMR). Strong quality assurance professional with a Doctor of Philosophy (Ph.D.) focused in Radiopharmaceutical Chemistry from Faculty of Pharmacy - Ain Shams University.

Radiopharmaceutical Chemistry

His current projects have led to the development of cardiovascular implants using nanomaterials and stem cell technology, and the development of organs using tissue engineering and nanoparticles for detection and treatment of cancer. He has also developed a family of nanomaterials and nanocomposite polymers for a range of biomedical applications. He was awarded the top prize in the field for development of nanomaterials and technologies for cardiovascular implants in 2007 by Medical Future Innovation, and in 2009 received a Business Innovation Award from UK Trade & Investment (UKTI) in the Life Sciences and Healthcare category. More recently (2011), he developed a lacrimal drainage conduit, vascular bypass graft, and trachea made from nanocomposite polymers and stem cells and delivered them from the laboratory directly to patients. In addition, he is also taking a further three products to clinical trials within the next three year, which include a coronary artery bypass graft in 2012, a transcatheter heart valve in 2013 (both funded by the Wellcome Trust), and a nerve conduit for nerve regeneration funded by the Technology Strategy Board (TSB).

Nanotechnology